Barrett & Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Barrett & Company’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.27K	Hold	12	–	–	﹤0.01%	571
2025 Q4	$2.04K	Hold	12	–	–	﹤0.01%	586
2025 Q3	$1.58K	Hold	12	–	–	﹤0.01%	594
2025 Q2	$1.27K	Hold	12	–	–	﹤0.01%	601
2025 Q1	$1.49K	Hold	12	–	–	﹤0.01%	573
2024 Q4	$1.48K	Hold	12	–	–	﹤0.01%	571
2024 Q3	$1.34K	Hold	12	–	–	﹤0.01%	549
2024 Q2	$1.28K	Sell	12 -3	-20%	-$330	﹤0.01%	561
2024 Q1	$1.83K	Hold	15	–	–	﹤0.01%	553
2023 Q4	$1.87K	Hold	15	–	–	﹤0.01%	536
2023 Q3	$1.97K	Buy	15 +3	+25%	+$400	﹤0.01%	547
2023 Q2	$1.49K	Hold	12	–	–	﹤0.01%	548
2023 Q1	$1.76K	Sell	12 -3	-20%	-$444	﹤0.01%	524
2022 Q4	$2.36K	Hold	15	–	–	﹤0.01%	505
2022 Q3	$2.36K	Buy	+15	New	+$2.28K	﹤0.01%	505

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Barrett & Company's JAZZ Position: Q1 2026 in Review

Barrett & Company held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 12 shares worth $2.27K. The position accounts for ﹤0.01% of the portfolio, ranked #571.

Barrett & Company first reported a position in JAZZ in Q3 2022 and has held it in 15 quarters since. The position peaked at $2.36K in Q4 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Barrett & Company held 12 shares of Jazz Pharmaceuticals worth $2.27K as of Q1 2026.
Barrett & Company left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Barrett & Company's portfolio in Q1 2026, its #571 holding.
Barrett & Company first reported a position in Jazz Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Barrett & Company's Jazz Pharmaceuticals position peaked at $2.36K in Q4 2022.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.